Insider Trading activities of Halozyme Therapeutics Inc insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Halozyme Therapeutics Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Halozyme Therapeutics Inc since year 2005. Table 2 shows the detailed insider transactions of Halozyme Therapeutics Inc since 2005. The reporting company's ticker symbol is HALO. The reporting company's CIK number is 1159036.
The total value of stock buying since 2005 is $117,790,806.
The total value of stock sales since 2005 is $23,117,013.
The total value of stock option exercises since 2005 is $3,644,687.


 1   2 
Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Halozyme Therapeutics Inc (HALO).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2018-06 0 $0 304,321 $5,186,691 8,918 $0
2018-04 0 $0 0 $0 6,875 $0
2018-02 0 $0 0 $0 187,408 $0
2018-01 0 $0 0 $0 30,000 $0
2017-06 0 $0 0 $0 6,875 $0
2017-05 0 $0 0 $0 20,000 $207,398
2017-04 0 $0 0 $0 6,875 $0
2017-02 0 $0 0 $0 143,766 $0
2017-01 0 $0 0 $0 37,500 $0
2016-06 0 $0 0 $0 26,825 $0
2016-04 0 $0 0 $0 6,875 $0
2016-02 0 $0 0 $0 31,250 $0
2016-01 0 $0 0 $0 57,500 $153,100
2015-09 0 $0 0 $0 20,000 $72,700
2015-08 10,000 $172,380 0 $0 10,000 $103,699
2015-06 0 $0 20,000 $420,000 10,000 $49,400
2015-03 0 $0 40,000 $613,400 0 $0
2015-02 0 $0 0 $0 12,426 $0
2015-01 0 $0 0 $0 30,000 $0
2014-12 0 $0 0 $0 37,683 $40,517
2014-09 75,000 $668,500 0 $0 50,000 $102,499
2014-08 0 $0 110,000 $1,095,740 150,000 $307,500
2014-05 0 $0 126,700 $957,978 150,000 $615,000
2014-02 0 $0 0 $0 34,873 $0
2013-12 0 $0 0 $0 56,419 $101,499
2013-09 0 $0 75,000 $685,049 230,000 $89,700
2013-08 100,000 $681,650 10,000 $71,090 20,000 $41,000
2013-02 0 $0 0 $0 59,373 $0
2012-11 85,000 $448,450 0 $0 0 $0
2012-08 22,000 $124,980 0 $0 0 $0
2012-06 194,189 $1,433,755 0 $0 0 $0
2012-05 1,091,498 $8,101,202 0 $0 43,065 $0
2012-02 1,360,000 $14,429,600 0 $0 0 $0
2011-11 920,947 $7,482,285 0 $0 0 $0
2011-08 1,014,000 $6,027,464 0 $0 0 $0
2010-01 0 $0 0 $0 30,000 $11,700
2008-12 10,000 $43,800 0 $0 0 $0
2008-06 1,908,491 $10,860,113 0 $0 0 $0
2008-03 4,566,245 $26,074,201 480,000 $2,908,800 869,902 $364,857
2007-12 0 $0 9,137 $63,959 52,496 $22,572
2007-11 0 $0 51,500 $409,289 85,317 $35,885
2007-10 0 $0 100,000 $896,540 83,191 $35,278
2007-09 470,000 $4,092,942 87,471 $779,217 109,105 $45,913
2007-08 0 $0 123,300 $1,024,051 204,381 $86,878
2007-07 0 $0 75,000 $702,065 117,940 $48,714
2007-06 0 $0 173,601 $1,701,973 216,152 $112,180
2007-05 3,500,000 $32,095,000 189,100 $1,968,998 47,500 $133,749
2007-04 0 $0 200,000 $1,772,475 125,000 $512,495
2007-03 80,280 $638,828 223,096 $1,859,698 180,833 $350,454
2006-12 481,200 $2,543,540 0 $0 0 $0
2006-09 282,500 $709,776 0 $0 0 $0
2006-08 421,600 $1,054,585 0 $0 0 $0
2005-08 23,000 $38,855 0 $0 0 $0
2005-05 35,000 $68,900 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Halozyme Therapeutics Inc insiders (HALO)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2018-06-29 Kirk Randal J Sale 122,431 16.97 2,077,654
2018-06-28 Kirk Randal J Sale 128,385 16.99 2,181,261
2018-06-27 Kirk Randal J Sale 53,505 17.34 927,776
2018-06-15 Stelzer Laurie (SVP, Chief Financial Officer) Option Ex 6,875 .00 0
2018-06-01 Chondros Dimitrios (SVP, Chief Medical Officer) Option Ex 2,043 .00 0
2018-04-13 Leonhardt Harry J (SVP, GC and CCO) Option Ex 6,875 .00 0
2018-02-22 Stelzer Laurie (SVP, Chief Financial Officer) Option Ex 11,392 .00 0
2018-02-22 Torley Helen (President and CEO) Option Ex 39,354 .00 0
2018-02-22 Leonhardt Harry J (SVP, GC and CCO) Option Ex 11,392 .00 0
2018-02-06 Torley Helen (President and CEO) Option Ex 31,250 .00 0
2018-02-03 Stelzer Laurie (SVP, Chief Financial Officer) Option Ex 23,120 .00 0
2018-02-03 Torley Helen (President and CEO) Option Ex 55,487 .00 0
2018-02-03 Leonhardt Harry J (SVP, GC and CCO) Option Ex 15,413 .00 0
2018-01-06 Torley Helen (President and CEO) Option Ex 30,000 .00 0
2017-06-15 Stelzer Laurie (SVP, Chief Financial Officer) Option Ex 6,875 .00 0
2017-05-11 Kirk Randal J Option Ex 10,000 10.37 103,699
2017-05-08 Matsui Connie Option Ex 10,000 10.37 103,699
2017-04-13 Leonhardt Harry J (SVP, GC and CCO) Option Ex 6,875 .00 0
2017-02-06 Torley Helen (President and CEO) Option Ex 31,250 .00 0
2017-02-03 Stelzer Laurie (SVP, Chief Financial Officer) Option Ex 23,120 .00 0
2017-02-03 Countouriotis Athena (SVP and Chief Medical Officer) Option Ex 18,496 .00 0
2017-02-03 Torley Helen (President and CEO) Option Ex 55,487 .00 0
2017-02-03 Leonhardt Harry J (SVP, GC and CCO) Option Ex 15,413 .00 0
2017-01-06 Torley Helen (President and CEO) Option Ex 30,000 .00 0
2017-01-05 Countouriotis Athena (SVP and Chief Medical Officer) Option Ex 7,500 .00 0
2016-06-30 Countouriotis Athena (SVP and Chief Medical Officer) Option Ex 6,450 .00 0
2016-06-30 Torley Helen (President and CEO) Option Ex 13,500 .00 0
2016-06-15 Stelzer Laurie (SVP, Chief Financial Officer) Option Ex 6,875 .00 0
2016-04-13 Leonhardt Harry J (SVP, GC and CCO) Option Ex 6,875 .00 0
2016-02-06 Torley Helen (President and CEO) Option Ex 31,250 .00 0
2016-01-13 Falberg Kathryn E Option Ex 20,000 7.66 153,100
2016-01-06 Torley Helen (President and CEO) Option Ex 30,000 .00 0
2016-01-05 Countouriotis Athena (SVP and Chief Medical Officer) Option Ex 7,500 .00 0
2015-09-14 Matsui Connie (Director) Option Ex 20,000 3.63 72,700
2015-08-28 Kelley Kenneth J Option Ex 10,000 10.37 103,699
2015-08-20 Stelzer Laurie (Chief Financial Officer) Buy 10,000 17.24 172,380
2015-06-18 Kelley Kenneth J Sale 20,000 21.00 420,000
2015-06-05 Kelley Kenneth J (Director) Option Ex 10,000 4.94 49,400
2015-03-05 Kelley Kenneth J (Director) Sale 40,000 15.34 613,400
2015-02-06 Ramsay David A (VP and Chief Financial Officer) Option Ex 7,088 .00 0
2015-02-04 Ramsay David A (VP and Chief Financial Officer) Option Ex 2,213 .00 0
2015-02-02 Ramsay David A (VP and Chief Financial Officer) Option Ex 3,125 .00 0
2015-01-06 Torley Helen (President and CEO) Option Ex 30,000 .00 0
2014-12-22 Ramsay David A (VP and Chief Financial Officer) Option Ex 17,625 .00 0
2014-12-01 Ramsay David A (VP and Chief Financial Officer) Option Ex 20,058 2.02 40,517
2014-09-16 Torley Helen (President and CEO) Buy 50,000 8.92 446,000
2014-09-16 Ramsay David A (VP and Chief Financial Officer) Buy 25,000 8.90 222,500
2014-09-16 Ramsay David A (VP and Chief Financial Officer) Option Ex 50,000 2.05 102,499
2014-08-19 Patton John Stuart Sale 75,000 9.96 747,000
2014-08-19 Patton John Stuart Option Ex 75,000 2.05 153,750
2014-08-14 Engler Robert Sale 35,000 9.96 348,740
2014-08-14 Engler Robert Option Ex 75,000 2.05 153,750
2014-05-15 Engler Robert Sale 126,700 7.56 957,978
2014-05-15 Engler Robert Option Ex 150,000 4.10 615,000
2014-02-04 Shaffer James P (VP & Chief Commercial Officer) Option Ex 4,864 .00 0
2014-02-04 Ramsay David A (VP and Chief Financial Officer) Option Ex 2,213 .00 0
2014-02-04 Liu Jean I (VP & General Counsel) Option Ex 4,682 .00 0
2014-02-02 Shaffer James P (VP & Chief Commercial Officer) Option Ex 11,629 .00 0
2014-02-02 Ramsay David A (VP and Chief Financial Officer) Option Ex 3,125 .00 0
2014-02-02 Liu Jean I (VP & General Counsel) Option Ex 8,360 .00 0
2013-12-20 Ramsay David A (VP, Chief Financial Officer) Option Ex 6,419 .00 0
2013-12-11 Frost Gregory Ian (CEO, President) Option Ex 50,000 2.03 101,499
2013-09-16 Ramsay David A (VP and Chief Financial Officer) Option Ex 130,000 .39 50,700
2013-09-16 Patton John Stuart (Director) Sale 37,500 9.16 343,687
2013-09-13 Patton John Stuart (Director) Sale 37,500 9.10 341,362
2013-09-13 Patton John Stuart (Director) Option Ex 100,000 .39 39,000
2013-08-19 Shepard H. Michael (VP, Chief Scientific Officer) Sale 10,000 7.11 71,090
2013-08-14 Falberg Kathryn E (Director) Buy 50,000 6.91 345,700
2013-08-12 Frost Gregory Ian (CEO, President) Option Ex 20,000 2.05 41,000
2013-08-12 Falberg Kathryn E (Director) Buy 50,000 6.72 335,950
2013-02-02 Shepard H. Michael (VP, Chief Scientific Officer) Option Ex 11,798 .00 0
2013-02-02 Shaffer James P (VP & Chief Commercial Officer) Option Ex 11,232 .00 0
2013-02-02 Gustafson Kurt A (Vice President and CFO) Option Ex 12,467 .00 0
2013-02-02 Frost Gregory Ian (CEO, President) Option Ex 16,049 .00 0
2013-02-02 Liu Jean I (VP & General Counsel) Option Ex 7,827 .00 0
2012-11-29 Engler Robert (Director) Buy 15,000 5.57 83,550
2012-11-14 Shaffer James P (VP & Chief Commercial Officer) Buy 20,000 5.22 104,400
2012-11-13 Falberg Kathryn E (Director) Buy 50,000 5.21 260,500
2012-08-27 Kelley Kenneth J (Director) Buy 20,000 5.70 113,980
2012-08-13 Frost Gregory Ian (CEO, President) Buy 2,000 5.50 11,000
2012-06-05 Kirk Randal J Buy 5,463 7.48 40,863
2012-06-04 Kirk Randal J Buy 89,646 7.37 660,691
2012-06-01 Kirk Randal J Buy 99,080 7.39 732,201
2012-05-17 Kirk Randal J Buy 299,007 7.50 2,242,552
2012-05-16 Kirk Randal J Buy 344,910 7.44 2,566,130
2012-05-15 Shepard H. Michael (VP, Chief Scientific Officer) Option Ex 11,400 .00 0
2012-05-15 Gustafson Kurt A (Vice President and CFO) Option Ex 15,200 .00 0
2012-05-15 Frost Gregory Ian (CEO, President) Option Ex 16,465 .00 0
2012-05-15 Kirk Randal J Buy 427,581 7.35 3,142,720
2012-05-14 Kelley Kenneth J (Director) Buy 20,000 7.49 149,800
2012-02-10 Kirk Randal J Buy 1,360,000 10.61 14,429,600
2011-11-23 Kirk Randal J Buy 166,100 8.00 1,328,800
2011-11-22 Kirk Randal J Buy 55,146 8.11 447,234
2011-11-21 Kirk Randal J Buy 56,477 8.04 454,075
2011-11-16 Kirk Randal J Buy 175,520 8.19 1,437,508
2011-11-15 Kirk Randal J Buy 242,704 8.18 1,985,318
2011-11-14 Kirk Randal J Buy 220,000 8.13 1,788,600
2011-11-14 Engler Robert (Director) Buy 5,000 8.15 40,750
2011-08-10 Kirk Randal J Buy 261,669 6.13 1,604,030
2011-08-09 Gustafson Kurt A (Vice President and CFO) Buy 8,000 5.88 47,008
2011-08-09 Frost Gregory Ian (CEO, President) Buy 6,000 5.84 35,040
2011-08-09 Kirk Randal J Buy 738,331 5.88 4,341,386
2010-01-12 Lim Jonathan E (Chief Executive Officer) Option Ex 30,000 .39 11,700
2008-12-16 Engler Robert (Director) Buy 10,000 4.38 43,800
2008-06-23 Kirk Randal J Buy 741,695 5.62 4,230,125
2008-06-20 Kirk Randal J Buy 175,500 5.85 1,026,674
2008-06-19 Kirk Randal J Buy 59,900 6.02 360,598
2008-06-13 Kirk Randal J Buy 45,725 5.53 252,859
2008-06-12 Kirk Randal J Buy 57,000 5.42 308,940
2008-06-11 Kirk Randal J Buy 115,439 5.27 608,363
2008-03-20 Frost Gregory Ian (VP and Chief Scientific Off.) Sale 230,000 6.06 1,393,800
2008-03-20 Lim Jonathan E (President, CEO) Sale 250,000 6.06 1,515,000
2008-03-20 Little Robert J (VP, Chief Commercial Officer) Buy 9,000 5.97 53,775
2008-03-20 Kirk Randal J Buy 1,264,657 6.09 7,701,761
2008-03-19 Frost Gregory Ian (VP and Chief Scientific Off.) Option Ex 639,902 .43 275,157
2008-03-19 Lim Jonathan E (President, CEO) Option Ex 230,000 .39 89,700
2008-03-19 Kirk Randal J Buy 1,773,300 5.80 10,285,140
2008-03-18 Ramsay David A (Secretary, CFO) Buy 10,000 4.55 45,500
2008-03-18 Kirk Randal J Buy 415,092 4.57 1,896,970
2007-12-20 Frost Gregory Ian (VP and Chief Scientific Off.) Sale 9,137 7.00 63,959
2007-12-20 Frost Gregory Ian (VP and Chief Scientific Off.) Option Ex 9,736 .43 4,186
2007-12-11 Frost Gregory Ian (VP and Chief Scientific Off.) Option Ex 42,760 .43 18,386
2007-11-30 Lim Jonathan E (President, CEO) Sale 20,000 8.22 164,400
2007-11-30 Lim Jonathan E (President, CEO) Option Ex 20,000 .39 7,800
2007-11-21 Frost Gregory Ian (VP and Chief Scientific Off.) Sale 10,000 7.65 76,500
2007-11-21 Frost Gregory Ian (VP and Chief Scientific Off.) Option Ex 10,603 .43 4,559
2007-11-20 Frost Gregory Ian (VP and Chief Scientific Off.) Sale 11,700 7.93 91,832
2007-11-20 Frost Gregory Ian (VP and Chief Scientific Off.) Option Ex 12,374 .43 5,320
2007-11-09 Frost Gregory Ian (VP and Chief Scientific Off.) Option Ex 42,340 .43 18,206
2007-10-31 Lim Jonathan E (President, CEO) Sale 25,000 9.06 226,625
2007-10-31 Lim Jonathan E (President, CEO) Option Ex 25,000 .39 9,750
2007-10-25 Frost Gregory Ian (VP and Chief Scientific Off.) Sale 15,000 9.05 135,720
2007-10-25 Frost Gregory Ian (VP and Chief Scientific Off.) Option Ex 15,754 .43 6,774
2007-10-24 Frost Gregory Ian (VP and Chief Scientific Off.) Sale 15,000 9.00 135,030
2007-10-24 Frost Gregory Ian (VP and Chief Scientific Off.) Option Ex 15,747 .43 6,771
2007-10-16 Lim Jonathan E (President, CEO) Option Ex 26,690 .45 11,983
2007-10-16 Patton John Stuart (Director) Sale 15,000 9.02 135,300
2007-10-09 Patton John Stuart (Director) Sale 15,000 8.70 130,440
2007-10-02 Patton John Stuart (Director) Sale 15,000 8.89 133,425
2007-09-28 Frost Gregory Ian (VP and Chief Scientific Off.) Option Ex 52,602 .43 22,618
2007-09-28 Lim Jonathan E (President, CEO) Sale 25,000 8.77 219,300
2007-09-28 Lim Jonathan E (President, CEO) Option Ex 25,000 .39 9,750
2007-09-27 Frost Gregory Ian (VP and Chief Scientific Off.) Sale 15,000 8.96 134,325
2007-09-27 Frost Gregory Ian (VP and Chief Scientific Off.) Option Ex 15,757 .43 6,775
2007-09-26 Frost Gregory Ian (VP and Chief Scientific Off.) Sale 15,000 9.07 136,080
2007-09-26 Frost Gregory Ian (VP and Chief Scientific Off.) Option Ex 15,746 .43 6,770
2007-09-25 Patton John Stuart (Director) Sale 15,000 8.94 134,160
2007-09-19 Kirk Randal J Buy 23,085 9.00 207,765
2007-09-18 Patton John Stuart (Director) Sale 17,471 8.89 155,352
2007-09-18 Kirk Randal J Buy 15,489 8.87 137,387
 1   2 

Insider trading activities including stock purchases, stock sales, and option exercises of HALO listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Halozyme Therapeutics Inc (symbol HALO, CIK number 1159036) see the Securities and Exchange Commission (SEC) website.